Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Samsung
Manufacturing
Samsung Bio set to launch $1.8B buyout of Swiss CDMO PolyPeptide
Korea's Samsung Biologics has tapped into the booming peptide production market with plans to buy out Swiss CDMO PolyPeptide for $1.8 billion.
Kevin Dunleavy
Jul 20, 2026 11:37am
Takeda, Sun, Ono—Fierce Pharma Asia
Mar 14, 2025 8:45am
Takeda, WuXi, LianBio—Fierce Pharma Asia
Feb 16, 2024 8:24am
Takeda, Lonza, US legislation—Fierce Pharma Asia
Feb 2, 2024 8:15am
Roche, Eisai, Takeda and more—Fierce Pharma Asia
May 12, 2023 9:15am
For $323M, Samsung Bio purchases land to increase CDMO footprint
Jul 18, 2022 4:53pm
